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Background: The aim of the present study was to assess cognitive impairment in patients 
with chronic heart failure (CHF) and its associations with depressive symptoms and somatic 
indicators of illness severity, which is a matter of controversy.
Methods and results: Fifty-five patients with CHF (mean age 55.3 ± 7.8 years; 80% male; 
New York Heart Association functional class I–III) underwent assessment with an expanded 
neuropsychological test battery (eg, memory, complex attention, mental flexibility, psychomo-
tor speed) to evaluate objective and subjective cognitive impairment. Depressive symptoms 
were assessed using the Structured Clinical Interview for Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition (SCID) and a self-report inventory (Hospital Anxiety 
and Depression Scale [HADS]). A comprehensive clinical dataset, including left ventricular 
ejection fraction, peak oxygen uptake, and a 6-minute walk test, was obtained for all patients. 
Neuropsychological functioning revealed impairment in 56% of patients in at least one measure 
of our neuropsychological test battery. However, the Mini Mental State Examination (MMSE) 
could only detect cognitive impairment in 1.8% of all patients, 24% had HADS scores indicating 
depressive symptoms, and 11.1% met SCID criteria for a depressive disorder. No significant 
association was found between depressive symptoms and cognitive impairment. Left ventricular 
ejection fraction was related to subjective cognitive impairment, and peak oxygen uptake was 
related to objective cognitive impairment.
Conclusion: Cognitive functioning was substantially reduced in patients with CHF and should 
therefore be diagnosed and treated in routine clinical practice. Caution is advised when the 
MMSE is used to identify cognitive impairment in patients with CHF.
Keywords: chronic heart failure, cognitive impairment, neuropsychological testing, depressive 
symptoms, peak oxygen uptake, quality of life
Introduction
Chronic heart failure (CHF) is a frequent complication of heart disease, and is one 
of the main causes of hospitalization, morbidity, and mortality in Western society.1 
Clinically, significant depression is present in at least one in five patients with heart 
failure.2 Depression has high rates in both inpatient and outpatient settings, and 
predicts mortality.3,4 Quality of life is often also impaired in patients with CHF.5,6 
A frequently neglected aspect of the clinical picture in patients with CHF is their cog-
nitive functioning.7,8 Not only does cognitive impairment interfere with the patient’s 
performance of everyday activities, but also with the ability to adhere to a complex 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
879
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJGM.S23841International Journal of General Medicine 2011:4
medication regimen and dietary therapies. Recent findings in 
patients with CHF have suggested structural brain injury in 
areas involved in cognitive, language, pain, and mood   function.9 
Although several reports10,11 indicate that a   considerable 
number of patients with CHF (20%–80%, depending on age) 
display deficits in cognitive abilities, the determinants and 
mechanisms of these deficits are not clear due to the   paucity 
of systematic investigations.12,13 Until now, most of the rel-
evant studies have only included small or geriatric samples, 
or focused on patients with end-stage heart failure in 
New York Heart Association (NYHA) functional class IV .8,14 
  Furthermore, the findings remain controversial.8,15
Some of the controversies in this field pertain to a lack of 
evidence as to the pathophysiology of cognitive impairment in 
CHF. The current hypotheses for cognitive impairment in heart 
failure include structural and functional changes in the brain 
related to vascular events due to emboli, cerebral hypoperfusion, 
and impaired cerebral vascular reactivity.16–18 Several groups, 
including Woo et al, have reported that patients with heart 
failure have significantly less gray matter volume than healthy 
subjects in specific regions of the brain.19 Moreover, Siachos 
et al reported that the prevalence of silent strokes in patients 
with heart failure was 34%,20 and other investigators found 
functional changes in patients showing significant reductions 
in regional blood flow compared with healthy subjects.21
However, the associations of cognitive functioning with 
cardiac output found in the literature are inconsistent. Whereas 
several investigators11,22,23 have noted that neuropsychological 
scores are not associated with cardiac output, other researchers 
have reported a significant association between cognitive func-
tioning and left ventricular ejection fraction (LVEF).24 Because 
cognitive impairment may also occur secondary to depressive 
symptoms or other psychiatric problems, the relationship 
between depressive symptoms, cognitive functioning, and 
somatic indicators of illness severity (ie, LVEF, peak oxygen 
uptake, and walking distance) in patients with CHF is of utmost 
importance in this area of research.8,15 However, only a few 
investigators have directly assessed cognitive performance and 
its association with depressive symptoms and somatic indica-
tors of illness severity in patients with CHF.15 Trojano et al, for 
example, demonstrated a predictive effect of depressive symp-
toms on neuropsychological performance in geriatric patients 
using the Geriatric Depression Scale.10 In contrast, Strauss et al 
did not find any associations between depressive symptoms 
and cognitive impairment in older patients with CHF.25 Only 
  Bornstein et al, evaluating 62 patients with end-stage CHF, 
noted a weak but significant association between depressive 
symptoms and cognitive impairment (r = 0.29, P , 0.02).14
In light of the important clinical relevance of this topic, 
we assessed cognitive impairment in a sample of middle-
aged patients with CHF (NYHA functional class I–III) using 
an expanded neuropsychological test battery and evaluated 
the specific associations between cognitive impairment, 
clinically significant depressive symptoms, and clinical 
parameters of CHF. Our first hypothesis was that, compared 
with standard indications derived from data in healthy con-
trols, the performance of patients with CHF on neuropsy-
chological tasks would be impaired. Our second hypothesis 
was that cognitive impairment in patients with CHF would 
be associated with depressive symptoms, clinical parameters 
of CHF, and quality of life variables.
Materials and methods
Sample
The study was based on analysis of 55 patients (mean age 
55.3 ± 7.8 years, 44 males, 11 females) with stable CHF, 
ie, NYHA functional class I–III. Patients were recruited 
consecutively. Inclusion criteria were stable documented 
CHF and LVEF #45%. Patients who had neurological and 
known psychiatric problems including overt dementia were 
excluded, as were those who had orthopedic, peripheral vas-
cular, renal, or severe pulmonary diseases which could impair 
successful completion of submaximal or maximal exercise 
tests. Of 885 screened patients, only 64 were recruited 
because of a large majority of the patients being ineligible 
due to LVEF .45% or unstable clinical status. The dropout 
rate, which includes 4% of missing data, was 15% (patients 
became clinically unstable or developed illnesses, or were 
not available for complete testing). In the end, we had the 
complete data of 55 patients for our analyses. To obtain an 
estimate of the required sample size, we assumed that in a 
full multiple regression model with independent variables of 
LVEF, peak oxygen uptake, walk test, and HADS depression 
score, an R2 of about 0.2 would be obtained. Additionally 
we assumed a reduced model that contained three irrelevant 
independent variables. With 80% power and an alpha of 0.05, 
45 cases would be necessary to obtain a squared semipartial 
correlation of the relevant independent variable of 0.2 with 
the criterion, which is equivalent to the difference between 
the full and reduced models. Sample size estimation was 
performed using SAS (v 9.2; SAS Institute Inc, Cary, NC).
Setting
The patients were referred to the Department of Cardiology 
at the University Hospital of Heidelberg, Germany. Assess-
ment and examination procedures were conducted within 
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4 weeks of initial screening and assessment. Each patient’s 
history, clinical status, sociodemographic variables, and the 
etiology of heart failure were assessed. Cardiopulmonary 
exercise testing (peak oxygen uptake), assessment of LVEF, 
and a 6-minute walk test were conducted on the same day. 
In order to avoid exhaustion, testing for cognitive func-
tioning and depressive symptoms was either done on the 
same day, before the clinical tests, or on another day. Short 
Form (SF)-36 questionnaires were sent to the patients and 
returned by mail. Recruitment, neuropsychological testing, 
and assessment of depression were carried out by GS and 
MB; 15% of the patients were retested separately by GS and 
MB, and interrater reliability was satisfactory. Procedures 
to assess indicators of illness severity (equilibrium radionu-
clide ventriculography, cardiopulmonary exercise testing, 
6-minute walk test) were carried out by medical staff and 
trained physicians in the department. Ethical approval for 
the study was obtained from the institutional review board 
at the Medical Faculty, University of Heidelberg. All the 
patients gave their written informed consent.
Assessment of cognitive impairment
All participants were evaluated with a battery of neuropsy-
chological tests designed to assess orientation, verbal and 
digit memory, complex attention, visuomotor skills, concept 
formation, language functioning, praxis, calculation, cogni-
tive and motor speed, and mental flexibility. The German 
versions of the battery of tests included the Trail Making 
Test A,26 a Verbal Learning List,27 a digit symbol test,27 and a 
digit recall procedure.28 The Trail Making Test A, the Verbal 
Learning List, and the digit symbol test were administered in 
two versions, one of them adapted to subjects aged 55 years 
or older. Additionally, the Mini Mental State Examination 
(MMSE) was administered to all participants.29 The Cere-
bral Insufficiency Self Report Inventory (CIS) was used to 
assess subjective cognitive impairment (SCI) by 38 “yes or 
no” items referring to difficulties in everyday activities.30 
A score of 20 or more indicates cognitive impairment. All 
tests produce valid and reliable measures of general cogni-
tive abilities.26–30
Assessment of depression
The Structured Clinical Interview for Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition (SCID)31,32 
served as the criterion for a depressive disorder. In addition, 
depressive symptoms were evaluated by the German version 
of the Hospital Anxiety and Depression Scale (HADS), a self-
rating inventory using seven items to assess for depressive 
symptoms.33 A total score $8 indicates clinically significant 
depressive symptoms. This instrument was chosen over other 
scales assessing depressive symptoms because of minimal 
item overlap between items referring to somatic symptoms 
and items referring to heart failure. The HADS scale is a well 
established self-report inventory to assess depressive symp-
toms, and has proven to have good operating characteristics.34 
The average time taken to assess cognitive functioning and 
depressive symptoms was about 50 minutes.
Assessment of health-related quality  
of life
Patient self assessment of health-related quality of life was 
measured by the German version of the SF-36.35 The SF-36 
is a generic multidimensional instrument consisting of eight 
scales representing physical functioning, role functioning 
physical, bodily pain, general health perceptions, vitality, 
social functioning, role functioning emotional, and mental 
health. SF-36 scores are converted to a scale of 0–100, with 
higher scores indicating a better quality of life.
Assessment of somatic indicators  
of illness severity
To determine LVEF, equilibrium radionuclide ventriculography 
was performed with a multicrystal gamma camera in the left 
anterior oblique view. Cardiopulmonary exercise testing was 
used to determine the functional capacity of the subjects. 
Equipment included a metabolic cart with an interfaced 
supine positioned bicycle ergometer. Peak oxygen uptake 
was defined as the maximum oxygen consumption measured 
during the last 30 seconds of symptom-limited exercise. Sub-
maximal exercise capacity was evaluated with the 6-minute 
walk test within 24 hours, and at least 4 hours before car-
diopulmonary exercise.
Statistical analyses
In a first step, neuropsychological test battery scores were trans-
formed into z values adapted for age and education. All z scores 
#−0.8 were classified as cognitive impairments. Pearson’s 
correlation coefficients were computed for the relationship 
between neuropsychological scores, clinical variables (LVEF, 
peak oxygen uptake, walking distance in the 6-minute walk 
test), depression (HADS), and quality of life scores (SF-36). 
Additionally, 95% confidence intervals were estimated for the 
mean. Chi-square tests (HADS, total score $ 8 as cutoff) with 
Bonferroni’s correction for multiple comparisons and t-tests 
(SCID) were used to compare the neuropsychological data of 
depressed and nondepressed patients.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
881
Heart failure and cognitive impairmentInternational Journal of General Medicine 2011:4
In a second step, two regression analyses were conducted, 
with the dependent variables being objective and subjective 
cognitive impairment. Depression (HADS), peak oxygen 
uptake, LVEF, and walking distance were used as indepen-
dent variables.
The objective cognitive impairment variable was gener-
ated by a factor analysis of all scores from the neuropsycho-
logical battery of tests. Factor analysis was computed with 
varimax rotation, and the factors could easily be interpreted as 
reflecting the Verbal Learning List, Trail Making Test A, and 
Digit Symbol Test. We used principal component analysis. 
Two factors were retained by the Eigenvalues .1 criterion. 
Varimax rotation showed a factor with high loadings on 
the Verbal Learning List, Trail Making Test A, and Digit 
Symbol Test. Because completion of the Digit Symbol Test 
did not always correspond to completion of the Trail Making 
Test A and Verbal Learning List, we decided to compute 
the unweighted sum of the Verbal Learning List and Trail 
Making Test A as a summary measure for objective cogni-
tive impairment (OCI). The CIS summary score was used 
for the subjective cognitive impairment variable. Statistical 
analyses were performed using SAS (v 6.0).
Results
Demographic data and clinical parameters for all patients are 
shown in Table 1. Eighty percent of the patients were male 
and had a cardiological diagnosis of dilated cardiomyopathy 
(60.0%) or coronary artery disease (23.6%). Their mean 
LVEF was 22.4% ± 12.8%, and 61.8% had NYHA class II, 
35.5% had NYHA class III, and 7.3% had NYHA class I 
symptoms. None of the patients was in NYHA class IV . Mean 
peak oxygen uptake was 14.3 ± 5.2 mL/min/kg.
The prevalence of cognitive impairment (as defined 
by the tests) in at least one measure of the objective 
neuropsychological battery of tests (OCI) was 43.6% com-
pared with normative values reported for healthy adults.26–30 
Forty percent of the patients reported SCI. Altogether, 56% 
of the patients showed deficits in their cognitive capacity 
in at least one objective or subjective measure (OCI and/
or SCI), 31% in at least two instruments, and 11% in three 
instruments. Thirteen percent showed subjective deficits but 
no objective impairment. Most deficits occurred in the Verbal 
Learning List and the Trail Making Test A, indicating impair-
ment in complex attention, verbal memory, and cognitive and 
psychomotor speed. Single test measures and prevalences of 
cognitive impairment are shown in Tables 2 and 3.
In contrast with the other measures of our neuropsycho-
logical test battery, the MMSE detected cognitive deficits in 
only 1.8% of the patients. There was no significant   difference 
between neuropsychological outcomes in patients with 
dilated cardiomyopathy, coronary artery disease, and other 
etiologies of CHF (all P $ 0.05).
Using the DSM IV criteria for depressive disorders, 
11.1% of the interviewed patients met the criteria for a current 
depressive disorder, 20% for a former depressive episode, 
and 25% met the diagnostic criteria for clinically signifi-
cant depressive symptoms according to the HADS (total 
score $8 as cutoff).
Correlation analyses revealed that higher subjective 
cognitive impairment was associated with lower scores on 
the SF-36 subscale of General Health Perceptions (r = −0.44; 
P , 0.01). No other significant correlations were found 
between the SF-36 subscales and the neuropsychological 
tests. High and significant correlations (P , 0.001) were 
found between depressive symptoms (HADS) and quality 
of life variables (SF-36), ie, mental health (r = −0.74), total 
score (r = −0.70), social functioning (r = −0.68), general 
Table 1 Demographic and clinical characteristics of patients
n 55
Age (years) 55.3 ± 7.8
Males/females (%) 80.0/20.0
Education $8 years (%) 54.5
Body mass index (kg/m2, SD) 23.8 ± 8.6
Cardiological diagnosis (%)
  Dilated cardiomyopathy 60.0
  Coronary artery disease 23.6
  Others 16.4
NYHA functional class (%)
  Class I 7.3
  Class II 61.8
  Class III 35.5
  Class IV 0.0
pVO2 (mL/min/kg; mean, SD) 14.3 ± 5.2
LVEF (%; mean, SD) 22.4 ± 12.8
6-minute walk test (mean, SD) 473.4 ± 122.3
SCID, current depressive disorder (%) 11.1
HADS $ 8 (%) 25.0
SF-36 (%, SD)
  Role functioning physical 37.2 ± 42.3
  General health perceptions 39.5 ± 17.3
  Vitality 41.5 ± 20.4
  Physical functioning 48.1 ± 24.5
  Role functioning emotional 54.6 ± 45.3
  Mental health 60.2 ± 19.6
  Bodily pain 64.4 ± 29.2
  Social functioning 71.0 ± 23.9
Total score 52.1 ± 21.0
Abbreviations: LVEF, left ventricular ejection fraction; pVO2, peak oxygen uptake; 
NYHA,  New  York  Heart  Association;  SCID,  Structured  Clinical  Interview  for 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; HADS, Hospital 
Anxiety and Depression Scale; SD, standard deviation; SF-36, Short Form 36.
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health perceptions (r = −0.65), vitality (r = −0.62), physical 
functioning (r = −0.51), bodily pain (r = −0.47), role func-
tioning emotional (r = −0.44) and role functioning physical 
(r = −0,38) (all P , 0.05). Regarding neuropsychological 
performance, depressed and nondepressed patients did not 
differ significantly (according to SCID diagnosis and HADS 
score, t-tests and Chi-square tests, see Tables 3 and 4).
Regression analyses for OCI
Univariate analyses revealed that none of the indepen-
dent variables were significantly associated with OCI (all 
P $ 0.05, see Table 5). In the multivariate regression model, 
only peak oxygen uptake was significantly associated with 
OCI (P = 0.04, β = 0.39). The depression variable (HADS) 
was not significantly related to OCI in the univariate or 
  multivariate analyses (P = 0.60 and 0.94, respectively).
Regression analyses for SCI
Univariate analyses revealed that none of the indepen-
dent variables were significantly associated with SCI (all 
P $ 0.05). The multivariate regression model revealed LVEF 
as being significantly associated with SCI (P = 0.04, β = 0.33). 
The depression variable (HADS) was not significantly related 
to SCI in the univariate or multivariate analyses (P = 0.71 
and 0.69, respectively). Altogether, neither the correlation, 
t-tests, Chi-square procedures, nor the univariate or multi-
variate analyses revealed significant associations between 
cognitive status and depressive symptoms.
Discussion
The objectives of this study were to assess cognitive 
impairment in middle-aged patients with CHF (mean age 
55.3 ± 7.8 years) using an expanded neuropsychological 
test battery and to analyze the specific associations between 
cognitive impairment, depressive symptoms, and clinical 
variables in these patients. First of all, we found substantially 
reduced neuropsychological performance in our patients 
(56% were impaired in at least one objective or subjective 
measure compared with normative values for healthy adults) 
regarding a variety of cognitive domains, such as memory, 
complex attention, and psychomotor speed. Furthermore, 
these impairments seem to be independent of CHF etiology, 
Table 2 Prevalence in cognitive impairment
Deficits in
One test of 5 (OCI or SCI) 56.0%
Two tests out of 5 (OCI and/or SCI) 31.0%
Three tests out of 5 (OCI and/or SCI) 11.0%
One test out of 4 (OCI) 43.6%
SCI, no OCI 13.0%
Deficits in
Verbal Learning List (OCI) 23.6%a
TMT-A (OCI) 20.0%a
Digit Symbol Test (OCI) 9.1%a
Digit Recall (OCI) 5.6%a
CI Self Inventory (SCI) 40.1%b
MMSE 1.8%c
Notes: az value #−0.8; btotal score $20; ctotal score ,24. 
Abbreviations:  OCI,  objective  cognitive  impairment;  SCI,  subjective  cognitive 
impairment;  MMSE,  Mini  Mental  State  Examination;  CI  Self  Inventory,  Cerebral 
Insufficiency Self Inventory.
Table 3 Neuropsychological battery of tests
Test 
(German version)
Domain Total group 
deficient 
test scores 
(%)
Non-depressed (SCID) 
z-value/score 
M (SD) 
n = 39
Depressed (SCID) 
z-value/score 
M (SD) 
n = 10
t df P valuea
Trail Making Test A Attention, cognitive 20.0b −0.25 (0.71) −0.84 (0.80) 2.29 47 0.03
(Zahlen-Verbindungs-Test) and motor speed
Verbal Learning List Immediate and 23.6b 0.244 (1.04) 0.239 (0.93) 0.02 47 0.98
(Wortliste) delayed recall
Digit Symbol Test Complex attention 9.1b 0.46 (0.73) −0.07 (0.84) 1.98 48 0.05
(Zahlen-Symbol-Test) visuo-motor skills
Digit Recall Memory, concentration 5.6b 0.43 (0.93) 0.24 (1.05) 0.56 46 0.58
(Zahlennachsprechen) concept formation
Cerebral Insufficiency Self  
Inventory (Cerebrale-
Insuffizienz-Skala)
Subjective cognitive  
impairment
40.1c 16.31 (7.53) 19.8 (5.59) −1.37 47 0.18
Mini Mental State Orientation, attention 1.8d
(Mini-Mental-Status-Test) immediate and delayed
recall, calculation
Notes: aCorrected by Bonferroni procedure: 0.01; SCID = Structured Clinical Interview DSM IV; bz-value #−0.8; ctotal score $ 20; dtotal score , 24. 
Abbreviations: SCID, Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; SD, standard deviation.
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in that our study revealed no significant differences regarding 
cognitive performance between patients with different CHF 
etiologies, such as dilated cardiomyopathy or coronary artery 
disease. Therefore, our first hypothesis was confirmed.
In contrast with the high overall rate of cognitive impair-
ment in our sample, the MMSE could detect cognitive 
impairment in only 1.8% of the patients. This finding suggests 
that the MMSE might not be sensitive enough to diagnose 
minor or even moderate forms of cognitive impairment in 
patients with CHF. Altogether, our results are in line with 
earlier studies, which also found high rates of cognitive 
impairment in patients with CHF. Since these studies inves-
tigated mostly cognitive functioning in end-stage geriatric 
patients, they often reported even higher rates of cognitive 
impairment.15–17,36 In contrast with other studies, we investi-
gated a middle-aged sample, and 56% of the patients were 
found to have objective or subjective impairment. This is 
quite surprising, given that we associate CHF mainly with 
elderly people.
Our study confirms the evidence of high prevalence 
rates of depressive symptoms in patients with CHF.2,5 Using 
DSM IV criteria, the prevalence of current depression or 
dysthymia was 11.1%. The self-report inventory, HADS, 
revealed a prevalence of clinically significant depressive 
symptoms of 25%. These differences in prevalence rates are 
most likely due to depression assessment by either interview 
or self-report inventory. Assessing depressive symptoms by 
interview usually leads to lower prevalence rates compared 
with self-report inventories.2
Contrary to our expectation of a linkage between cogni-
tive impairment and depressive symptoms in patients with 
CHF, there was no significant association between OCI or 
SCI and depressive symptoms (SCID, HADS). Similar results 
were found regarding quality of life. Because depressive 
symptoms and quality of life are overlapping variables, both 
were significantly related to each other, but neither depres-
sion nor quality of life was related to cognitive impairment, 
except for the correlation between SCI and the SF-36 sub-
scale of General Health Perception. This finding is rather 
surprising, given that reciprocal enhancement could have 
been assumed.
Whereas the present pattern of results matches the 
results of previous studies,15,19,23,37 that is, depressive 
symptoms are unrelated to cognitive impairment in 
patients suffering from heart failure, the present data are 
also in conflict with those publications which found an 
association between depressive symptoms and cognitive 
Table 4 Neuropsychological battery of tests
Test 
(German version)
Domain Non-depressed (HADS) 
z-value/score 
M (SD) 
n = 33
Depressed (HADS) 
z-value/score 
M (SD) 
n = 13
χ2  df P valuea
Trail Making Test A Attention, cognitive −0.26 (0.62) −0.83 (0.91) 3.29 1 0.07
(Zahlen-Verbindungs-Test) and motor speed
Verbal Learning List Immediate and 0.07 (1.01) 0.42 (0.80) 0.98 1 0.32
(Wortliste) delayed recall
Digit Symbol Test Complex attention, 0.42 (0.73) 0.12 (0.85) 0.00 1 0.99
(Zahlen-Symbol-Test) visuo-motor skills
Digit Recall Memory, concentration, 0.43 (0.87) 0.31 (1.22) 0.96 1 0.33
(Zahlennachsprechen) concept formation
Cerebral Insufficiency Self Inventory Subjective cognitive 16.8 (7.68) 18.3 (6.64) 0.10 1 0.75
(Cerebrale-Insuffizienz-Skala) impairment
Note: aCorrected by Bonferroni procedure: 0.01. 
Abbreviations: HADS, Hospital Anxiety and Depression Scale; SD, standard deviation.
Table 5 Univariate and multivariate regression analysis: physical 
variables and depressive symptoms as predictors for objective 
and subjective cognitive impairment
Variable Subjective  
cognitive  
impairment
Objective 
cognitive 
impairment
β value P value β value P value
Univariate
pVO2 (mL/min/kg) −0.19 0.41 0.20 0.16
LVEF (%) 0.24 0.11 −0.17 0.25
6-minute walk test (m) 0.01 0.95 0.069 0.64
Depressive symptoms 
(HADS)
0.27 0.71 0.01 0.94
Multivariate
pVO2 (mL/min/kg) −0.25 0.15 0.39 0.04
LVEF (%) 0.33 0.04 −0.13 0.45
6-minute walk test (m) 0.13 0.44 −0.12 0.51
Depressive symptoms 
(HADS)
0.28 0.069 0.08 0.60
Abbreviations: pVO2, peak oxygen uptake; LVEF, left ventricular ejection fraction; 
HADS, Hospital Anxiety and Depression Scale.
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impairment.14,38–41 It is conceivable that these conflicting 
findings are due to different samples (recruitment, sample 
size, age of patients) and to the different instruments to 
assess cognitive impairment, as well as due to the different 
methods used to evaluate depressive symptoms. For instance, 
in the investigation of Pullicino et al,38 the cognitive status 
of an older sample (mean age 64.7 years) was assessed only 
by one measure, ie, the six-item screener derived from the 
MMSE. In this population, there was a considerable rate of 
prior stroke compared with our study population which did 
not have a main diagnosis of vascular etiology. Lopez et al39 
investigated a sample of older adults with mild cognitive 
impairment (mean age at least 74.0 years), of whom a sig-
nificantly high percentage suffered from depression and had 
poor neuroradiological results, such as white matter lesions, 
cortical atrophy, and infarcts identified by magnetic reso-
nance imaging. These vascular and neurodegenerative factors 
may have contributed to cognitive impairment in the sample 
reported by Lopez et al. As a consequence, it is difficult to 
compare this sample with our sample. Likewise, Thomas and 
O’Brien40 focused in their review mainly on depression in 
later life and mentioned the conflicting literature on whether 
depression is a risk factor for cognitive decline or not. Next, 
in their prospective longitudinal study, Barnes et al41 inves-
tigated a random sample of adults aged 65 years and older. 
Their results showed that worse depressive symptoms were 
associated with an increased risk of cognitive decline and 
dementia. These findings suggest that depressive symptoms 
in the absence of overt cognitive impairment may reflect 
early signs of neurodegenerative disease in older patients. 
Furthermore, an item overlap, eg, in the CES-D scale (state-
ments that reflect aspects both of mood and cognition) has to 
be considered. To avoid item overlap with physical fatigue, 
for instance, which occurs due to heart failure, we used the 
HADS instrument. Because our sample consisted of middle-
aged patients diagnosed with dilated cardiomyopathy in 60% 
of cases, neurodegenerative and cerebrovascular aspects as a 
possible link between cognitive impairment and depression 
seem to play a less important role than in a sample of elderly 
patients. Regarding the somatic indicators of illness severity, 
our results revealed that cognitive impairment is more associ-
ated with reduced functional capacity than depression. In the 
final regression model, peak oxygen uptake was significantly 
related to OCI. Furthermore, SCI was related to LVEF. These 
results suggest that cognitive impairment might be second-
ary to deficits in blood supply in our sample. However, data 
concerning a relationship between LVEF and cognitive 
impairment are inconsistent. Whereas some studies22,23 found 
that neuropsychological scores were not related to cardiac 
output, others did find a relationship with LVEF.24
In summary, our data indicate that depression and 
cognitive impairment are independent comorbidities in 
middle-aged patients with CHF. Further studies which also 
differentiate between OCI and SCI could be promising in 
clarifying this specific relationship and its underlying mecha-
nisms. Our investigation has limitations that need to be taken 
into account, so the present pattern of results should not be 
overinterpreted. First, impaired cognitive functioning was 
classified as at least one cognitive measure out of the battery 
of neuropsychological tests falling below z scores #−0.8 
(OCI), or/and showing a total score beyond the cutoff value 
of the Cerebral Insufficiency Self Report Inventory (SCI). 
Other researchers might apply different algorithms. Second, 
it is important to mention that, to the best of our knowledge, 
it is still a matter of debate as to which z score best reflects 
the onset of cognitive impairment. Third, it remains unclear 
which of the numerous instruments and measures reliably 
reflects cognitive impairment in this specific sample of 
middle-aged patients suffering from heart failure. As a con-
sequence, future research should use alternative instruments 
to assess executive function.
Furthermore, the study was performed at a tertiary refer-
ral center. Therefore, the sample of patients with CHF as the 
main etiology does not represent typical patients with CHF 
seen by a general practitioner. These patients might show less 
impairment of LVEF and demonstrate a higher prevalence 
of coronary artery disease.42 Hence, our data may not be 
representative of patients in primary care or in the general 
population. It must also be pointed out that the cross-sectional 
design of the present study does not permit conclusions to 
be drawn concerning causality. However, the present data 
show a clear association between cognitive impairment and 
indicators of illness severity, whereas depressive symptoms 
and cognitive deficits do not show any association.
Conclusion
In this study, we found that CHF was associated with signifi-
cant levels of cognitive impairment and depressive symptoms 
in a middle-aged sample of patients with NYHA functional 
class I–III disease, and whereas cognitive scores were sig-
nificantly associated with peak oxygen uptake and LVEF, 
no significant association was found between cognitive 
impairment and depressive symptoms. Successful therapeutic 
management of CHF often depends heavily on the patient’s 
understanding of and adherence to a complex medication 
regimen and a strict diet. Cognitive impairment, such as 
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memory and attention difficulties, can be very problematic 
in this context because they might interfere with the patient’s 
ability to adhere to medication and dietary therapies. Thus, 
cognitive impairment could possibly contribute to weakened 
compliance of patients with CHF with prescribed therapy 
and, as a consequence, increase the rate of hospital readmis-
sion. In light of the results of this study, reduced compliance 
in patients with depressive symptoms because of cognitive 
impairment seems highly unlikely. Physicians should be 
aware of these associations and be prepared to assess both 
the cognitive and affective state of patients in addition to 
physical parameters. However, even if the MMSE is largely 
applied in many clinical settings as the only instrument to 
assess cognition, it is not sensitive enough to identify mild or 
even moderate cognitive impairment in patients with CHF. 
Therefore caution is advised when the MMSE is applied 
as the sole measure to identify cognitive impairment in 
patients with CHF. Properly designed training programs to 
prevent, slow down, or cope with cognitive impairment, as 
well as implementation of depression screening programs in 
routine clinical practice could help to improve the treatment 
of patients with CHF and to prevent a progressive course 
of disease.
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